ConductScience.org, home

Paper37831007

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.

Wei D and 4 others. Clin Cancer Res, 2024. Cited by 145 papers, by iCite.

Cite this record

ConductScience Library. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. Papers, record 37831007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37831007

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
145
iCite
Relative citation ratio, by iCite
17.03, provisional
iCite
Revised in PubMed
2025-09-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Pancreatic NeoplasmsMajor topic
Carcinoma, Pancreatic DuctalMajor topic
Heterocyclic Compounds, 2-RingMajor topic
NaphthalenesMajor topic
Humans
Proto-Oncogene Proteins p21(ras)
Mutation

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P50 CA221707NCI NIH HHSUnited StatesP50CA221707PubMedNIH RePORTER
R01 CA236905NCI NIH HHSUnited StatesR01CA236905PubMed and NIHNIH RePORTER
R01 CA198090NCI NIH HHSUnited StatesR01CA198090PubMed and NIHNIH RePORTER
P30 DK056338NIDDK NIH HHSUnited StatesP30DK056338PubMed and NIHNIH RePORTER
R01 CA220236NCI NIH HHSUnited StatesR01CA220236PubMed and NIHNIH RePORTER

Download CSV of grants

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in39279937Mutant KRAS inhibitors enter the scene of precision therapeutics for pancreatic cancer.https://conductscience.org/library/papers/39279937PubMed
Comment in39279949MRTX1133's promise for treating KRASG12D-mutant pancreatic cancer.https://conductscience.org/library/papers/39279949PubMed

Download CSV of comments and corrections

References66

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126436951PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.Oncogenesis2015https://conductscience.org/library/papers/26436951PubMed
227010960KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma.Clin Transl Gastroenterol2016https://conductscience.org/library/papers/27010960PubMed
334518295Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.Mol Cancer Ther2021https://conductscience.org/library/papers/34518295PubMed
436618907Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation.Front Pharmacol2022https://conductscience.org/library/papers/36618907PubMed
522589270A comprehensive survey of Ras mutations in cancer.Cancer Res2012https://conductscience.org/library/papers/22589270PubMed
629229669KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.Cold Spring Harb Perspect Med2018https://conductscience.org/library/papers/29229669PubMed
724256730K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.Nature2013https://conductscience.org/library/papers/24256730PubMed
832250617Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.J Med Chem2020https://conductscience.org/library/papers/32250617PubMed
937059070Pancreatic cancer: Advances and challenges.Cell2023https://conductscience.org/library/papers/37059070PubMed
1021993244RAS oncogenes: weaving a tumorigenic web.Nat Rev Cancer2011https://conductscience.org/library/papers/21993244PubMed
1137277530An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.Nat Cancer2023https://conductscience.org/library/papers/37277530PubMed
1234547082Pancreatic Cancer: A Review.JAMA2021https://conductscience.org/library/papers/34547082PubMed
1326091808A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.Ann Oncol2015https://conductscience.org/library/papers/26091808PubMed
1435075146KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge.Cell Discov2022https://conductscience.org/library/papers/35075146PubMed
1532047043The small molecule BI-2852 induces a nonfunctional dimer of KRAS.Proc Natl Acad Sci U S A2020https://conductscience.org/library/papers/32047043PubMed
1626037647Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.Mol Cancer Res2015https://conductscience.org/library/papers/26037647PubMed
1732247999Immunotherapy for pancreatic cancer: A 2020 update.Cancer Treat Rev2020https://conductscience.org/library/papers/32247999PubMed
1837068173Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.Cancer Discov2023https://conductscience.org/library/papers/37068173PubMed
1932046984Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment.Cancer Discov2020https://conductscience.org/library/papers/32046984PubMed
2019208745KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin.Mol Cancer Res2009https://conductscience.org/library/papers/19208745PubMed

See all 66 referencesDownload CSV of references

Cited by103

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 145 citations.

PMIDTitleJournalYearIn PapersSource
42935756Metabolic sensing in 3D models of pancreatic ductal adenocarcinoma: probing pH, oxygen, and lactate dynamics to decode chemoresistance.Front Bioeng Biotechnol2026https://conductscience.org/library/papers/42935756PubMed
42840361KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine.MedComm (2020)2026https://conductscience.org/library/papers/42840361PubMed
42829436Targeting adaptive EGFR feedback enhances the therapeutic efficacy of RMC-6236 in cholangiocarcinoma.Exp Hematol Oncol2026https://conductscience.org/library/papers/42829436PubMed
42794928Advances in KRAS-Targeted Therapies for Pancreatic Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42794928PubMed
42712971RAS signaling and remodeling of the immune microenvironment in pancreatic ductal adenocarcinoma: implications of emerging RAS-targeted therapy.Front Cell Dev Biol2026https://conductscience.org/library/papers/42712971PubMed
42649442KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer.Ann Surg Oncol2026https://conductscience.org/library/papers/42649442PubMed
42645357Targeted Therapy in Pancreatic Ductal Adenocarcinoma: Current Advances and Challenges.Curr Oncol2026https://conductscience.org/library/papers/42645357PubMed
42629972Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study.Int J Cancer2027https://conductscience.org/library/papers/42629972PubMed
42622884KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Med Oncol2026https://conductscience.org/library/papers/42622884PubMed
42591541Bergamottin demonstrates preclinical effectiveness against pancreatic cancer by modulating PPAR-γ to induce apoptosis.Transl Cancer Res2026https://conductscience.org/library/papers/42591541PubMed
42528591Research progress of small molecule targeted drugs for non-small cell lung cancer.Front Oncol2026https://conductscience.org/library/papers/42528591PubMed
42520352Rac/Cdc42 inhibitors target pancreatic cancer cells and macrophages in the tumor microenvironment.Cancer Treat Res Commun2026https://conductscience.org/library/papers/42520352PubMed
42513436Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.J Clin Med2026https://conductscience.org/library/papers/42513436PubMed
42453876Therapeutic inhibition of RAS in non-small cell lung cancer.Front Oncol2026https://conductscience.org/library/papers/42453876PubMed
42422981Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer center.Future Oncol2026https://conductscience.org/library/papers/42422981PubMed
42393724KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.J Hematol Oncol2026https://conductscience.org/library/papers/42393724PubMed
42377115High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.Clin Cancer Res2026https://conductscience.org/library/papers/42377115PubMed
42370145Research progress on the etiology and pathogenesis of pancreatic cancer: a narrative review.Front Oncol2026https://conductscience.org/library/papers/42370145PubMed
42356482Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42356482PubMed
42327248Rosindol: A fluorogen for the quantitative measurement of reactive oxygen species in living cells.bioRxiv2026https://conductscience.org/library/papers/42327248PubMed

See all 103 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37831007

GET https://conductscience.org/api/papers/v1/37831007/references?page=2